IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Yung-Jue1; Van Cutsem, Eric2; Feyereislova, Andrea3; Chung, Hyun C.4; Shen, Lin5; Sawaki, Akira6; Lordick, Florian7; Ohtsu, Atsushi8; Omuro, Yasushi9; Satoh, Taroh10; Aprile, Giuseppe11; Kulikov, Evgeny12; Hill, Julie13; Lehle, Michaela3; Ruschoff, Josef14; Kang, Yoon-Koo15; ToGA Trial Investigators
刊名LANCET
2010-08-01
DOI10.1016/S0140-6736(10)61121-X
376期:9742页:687-697
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]METASTATIC BREAST-CANCER ; ADVANCED ESOPHAGOGASTRIC CANCER ; ADJUVANT CHEMOTHERAPY ; GENE AMPLIFICATION ; 1ST-LINE THERAPY ; SUPPORTIVE CARE ; III TRIAL ; PLUS ; HER2 ; FLUOROURACIL
英文摘要

Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer.

Methods ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries. Patients with gastric or gastro-oesophageal junction cancer were eligible for inclusion if their tumours showed overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation. Participants were randomly assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in combination with intravenous trastuzumak Allocation was by block randomisation stratified by Eastern Cooperative Oncology Group performance status, chemotherapy regimen, extent of disease, primary cancer site, and measurability of disease, implemented with a central interactive voice recognition system. The primary endpoint was overall survival in all randomised patients who received study medication at least once. This trial is registered with ClinicalTrials.gov, number NCT01041404.

Findings 594 patients were randomly assigned to study treatment (trastuzumab plus chemotherapy, n=298; chemotherapy alone, n=296), of whom 584 were included in the primary analysis (n=294; n=290). Median follow-up was 18.6 months (IQR 11-25) in the trastuzumab plus chemotherapy group and 17.1 months (9-25) in the chemotherapy alone group. Median overall survival was 13 8 months (95% Cl 1.2-16) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months (10-13) in those assigned to chemotherapy alone (hazard ratio 0.74; 95% Cl 0.60-0.91; p=0.0046). The most common adverse events in both groups were nausea (trastuzumab plus chemotherapy, 197 [67%] vs chemotherapy alone, 184 [63%]), vomiting (147 [50%] vs 134 [46%]), and neutropenia (157 [53%] vs 165 [57%])} Rates of overall grade 3 or 4 adverse events (201 [68%] vs 198 [68%]) and cardiac adverse events (17 [6%] vs 18 [6%]) did not differ between groups

Interpretation Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.

语种英语
WOS记录号WOS:000281582900028
Citation statistics
Cited Times:1191[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63644
Collection北京大学临床肿瘤学院
作者单位1.Roche Prod Ltd, Dee Why, NSW, Australia
2.Targos Mol Pathol, Kassel, Germany
3.Asan Med Ctr, Seoul, South Korea
4.Seoul Natl Univ, Coll Med, Seoul 110744, South Korea
5.Univ Hosp Gasthuisberg, B-3000 Leuven, Belgium
6.F Hoffmann La Roche, Basel, Switzerland
7.Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Seoul, South Korea
8.Peking Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China
9.Aichi Canc Ctr, Aichi, Japan
10.Natl Centrum Tumorerkrankungen, Heidelberg, Germany
11.East Hosp, Natl Canc Ctr, Kashiwa, Chiba, Japan
12.Komagome Gen Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
13.Kinki Univ, Sch Med, Osaka 589, Japan
14.Azienda Osped Univ, Udine, Italy
15.Reg Clin Oncol Dispensary, Ryazan, Russia
Recommended Citation
GB/T 7714
Bang, Yung-Jue,Van Cutsem, Eric,Feyereislova, Andrea,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. LANCET,2010,376(9742):687-697.
APA Bang, Yung-Jue.,Van Cutsem, Eric.,Feyereislova, Andrea.,Chung, Hyun C..,Shen, Lin.,...&ToGA Trial Investigators.(2010).Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.LANCET,376(9742),687-697.
MLA Bang, Yung-Jue,et al."Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial".LANCET 376.9742(2010):687-697.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Bang, Yung-Jue]'s Articles
[Van Cutsem, Eric]'s Articles
[Feyereislova, Andrea]'s Articles
百度学术
百度学术Similar articles in
[Bang, Yung-Jue]'s Articles
[Van Cutsem, Eric]'s Articles
[Feyereislova, Andrea]'s Articles
必应学术
必应学术Similar articles in
[Bang, Yung-Jue]'s Articles
[Van Cutsem, Eric]'s Articles
[Feyereislova, Andrea]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.